In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other and you, the reader, will determine the winner.
Celgene takes on Facebook for this first round-robin match up in our search for the better stock today.
Healthcare Analyst David Williamson believes the number one reason Celgene (NASDAQ:CELG) should win this match is its ability to open new sales possibilities for already approved drugs. By expanding indications -- having drugs used for multiple diseases -- management expects to double earnings from 2013 to 2017. Headlined by megablockbuster Revlimid, this big biotech is an oncology and autoimmune powerhouse, and its stock is showing no signs of slowing down.
Motley Fool Tech analyst, Jamal Carnette, thinks Facebook (NASDAQ:FB) should advance to the next round because of one big reason, the price still doesn't match its potential. Right now, Facebook is the first website many people visit in the morning and that's immensely valuable to Facebook's real customers -- marketers. In addition, Facebook is looking at growing both users and viewing times. Facebook has redefined the Internet, and will continue to grow its massive ad-based revenue at a healthy clip. That's why Facebook deserves to win this match.
Vote here to determine the winner of this match and sound off in the comments. Check back to Fool.com to see who advances in the tournament.
David Williamson owns shares of Facebook. Jamal Carnette has no position in any stocks mentioned. The Motley Fool recommends Celgene and Facebook. The Motley Fool owns shares of Facebook. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.